OTCMKTS:CNBTF

Cannara Biotech Competitors

$0.13

0.00 (0.00 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.13

Now: $0.13▼

$0.13

50-Day Range

$0.12

MA: $0.13▼

$0.14

52-Week Range

$0.08

Now: $0.13▼

$0.20

Volume10,000 shs

Average Volume33,127 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Cannara Biotech (OTCMKTS:CNBTF) Vs. SCCB, ACEVU, ACKIU, ADRAU, ADEXU, and IMPXU

Should you be buying CNBTF stock or one of its competitors? Companies in the industry of "--" are considered alternatives and competitors to Cannara Biotech, including 378 (SCCB), ACE Convergence Acquisition (ACEVU), Ackrell SPAC Partners I (ACKIU), Adara Acquisition (ADRAU), Adit EdTech Acquisition (ADEXU), and AEA-Bridges Impact (IMPXU).

Cannara Biotech vs. 378 Stock

Cannara Biotech (OTCMKTS:CNBTF) and 378 (OTCMKTS:SCCB) are both -- companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Cannara Biotech and 378's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cannara Biotech	N/A	N/A	N/A
378	N/A	N/A	N/A

Earnings & Valuation

This table compares Cannara Biotech and 378's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cannara Biotech	N/A	N/A	N/A	N/A	N/A
378	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cannara Biotech and 378, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cannara Biotech	0	0	0	0	N/A
378	0	0	0	0	N/A

Cannara Biotech vs. ACE Convergence Acquisition Stock

ACE Convergence Acquisition (OTCMKTS:ACEVU) and Cannara Biotech (OTCMKTS:CNBTF) are both -- companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Analyst Ratings

This is a summary of current ratings and recommmendations for ACE Convergence Acquisition and Cannara Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACE Convergence Acquisition	0	0	0	0	N/A
Cannara Biotech	0	0	0	0	N/A

Profitability

This table compares ACE Convergence Acquisition and Cannara Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ACE Convergence Acquisition	N/A	N/A	N/A
Cannara Biotech	N/A	N/A	N/A

Earnings & Valuation

This table compares ACE Convergence Acquisition and Cannara Biotech's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACE Convergence Acquisition	N/A	N/A	N/A	N/A	N/A
Cannara Biotech	N/A	N/A	N/A	N/A	N/A

Cannara Biotech vs. Ackrell SPAC Partners I Stock

Cannara Biotech (OTCMKTS:CNBTF) and Ackrell SPAC Partners I (OTCMKTS:ACKIU) are both -- companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares Cannara Biotech and Ackrell SPAC Partners I's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cannara Biotech	N/A	N/A	N/A
Ackrell SPAC Partners I	N/A	N/A	N/A

Valuation and Earnings

This table compares Cannara Biotech and Ackrell SPAC Partners I's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cannara Biotech	N/A	N/A	N/A	N/A	N/A
Ackrell SPAC Partners I	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cannara Biotech and Ackrell SPAC Partners I, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cannara Biotech	0	0	0	0	N/A
Ackrell SPAC Partners I	0	0	0	0	N/A

Cannara Biotech vs. Adara Acquisition Stock

Adara Acquisition (OTCMKTS:ADRAU) and Cannara Biotech (OTCMKTS:CNBTF) are both -- companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Profitability

This table compares Adara Acquisition and Cannara Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adara Acquisition	N/A	N/A	N/A
Cannara Biotech	N/A	N/A	N/A

Valuation & Earnings

This table compares Adara Acquisition and Cannara Biotech's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adara Acquisition	N/A	N/A	N/A	N/A	N/A
Cannara Biotech	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for Adara Acquisition and Cannara Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adara Acquisition	0	0	0	0	N/A
Cannara Biotech	0	0	0	0	N/A

Cannara Biotech vs. Adit EdTech Acquisition Stock

Adit EdTech Acquisition (OTCMKTS:ADEXU) and Cannara Biotech (OTCMKTS:CNBTF) are both -- companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Valuation & Earnings

This table compares Adit EdTech Acquisition and Cannara Biotech's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adit EdTech Acquisition	N/A	N/A	N/A	N/A	N/A
Cannara Biotech	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Adit EdTech Acquisition and Cannara Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adit EdTech Acquisition	N/A	N/A	N/A
Cannara Biotech	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Adit EdTech Acquisition and Cannara Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adit EdTech Acquisition	0	0	0	0	N/A
Cannara Biotech	0	0	0	0	N/A

Cannara Biotech vs. AEA-Bridges Impact Stock

AEA-Bridges Impact (OTCMKTS:IMPXU) and Cannara Biotech (OTCMKTS:CNBTF) are both -- companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares AEA-Bridges Impact and Cannara Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEA-Bridges Impact	N/A	N/A	N/A
Cannara Biotech	N/A	N/A	N/A

Earnings and Valuation

This table compares AEA-Bridges Impact and Cannara Biotech's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEA-Bridges Impact	N/A	N/A	N/A	N/A	N/A
Cannara Biotech	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AEA-Bridges Impact and Cannara Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEA-Bridges Impact	0	0	0	0	N/A
Cannara Biotech	0	0	0	0	N/A